Neoantigen player PACT Pharma woos Tim Moore from Kite to run technical ops
In cell therapy, some of the biggest breakthroughs lie not in the science of killing tumor cells but figuring out a way to manufacture those treatments at scale. Working on a personalized T cell therapy targeting neoantigens, PACT Pharma knows just how important — and difficult — it can be to recruit a top-notch leader for the technical team.
“There are only a handful of people at the center of the action,” CEO Alex Franzusoff noted in a statement.
One of them is now coming to PACT. Tim Moore, who oversaw the CAR-T buildout at Kite, will officially become its president and chief technical officer next week.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 67,500+ biopharma pros reading Endpoints daily — and it's free.